Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
Late-December 2024 sees the launch of Australia’s first government-backed clinical trial using AI-guided neuromodulation to tackle severe, treatment-resistant …
Caption By the end of 2024, emerging studies point to GLP‑1 receptor agonists—once mainly weight‑loss drugs—finding versatile application …
A landmark regulatory update aims to speed approvals, reduce bureaucracy, and strengthen the UK’s position as a global …
Semaglutide’s latest trial reveals significant reduction in heart failure hospitalizations, expanding its role in cardiometabolic care.
NIH-backed research reveals that a simple skin test may revolutionize early diagnosis of Parkinson’s and related neurodegenerative disorders.
Exploring recent advancements in CRISPR therapies, personalized gene editing, and artificial intelligence transforming drug development and clinical trials.
In 2024, the European Medicines Agency (EMA) recommended a record 114 new medicines for approval, showcasing major advances …
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
Cutting-edge mRNA technology is breaking new ground, offering hope for targeted treatments in autoimmune conditions beyond infectious diseases.
Australia’s National Genomic Registry is connecting patients, clinicians, and researchers to transform rare disease care in real time.
Already a subscriber? Log in